Epithalon

What Epithalon is and how it works

Epithalon, also written epitalon and abbreviated AEDG, is a tetrapeptide with the sequence Ala-Glu-Asp-Gly. Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology developed it as a defined counterpart to epithalamin, a peptide extract of animal pineal glands that the same school had worked on for years. The name points at the epiphysis, the older anatomical term for the pineal gland. Where the extract is a mixture, Epithalon is a single molecule, far easier to make, measure and compare between laboratories.

The school describes peptides of this length as bioregulators: short sequences that enter cells, interact with DNA or chromatin and change which genes are read. For Epithalon the gene of interest encodes the catalytic subunit of telomerase, the enzyme that rebuilds telomeres, the repeated caps on chromosome ends. Most human body cells make little or no telomerase, so their telomeres shorten with every division until the cell stops dividing, the limit Leonard Hayflick described.

No receptor for Epithalon has been identified, and the proposal that a four-residue peptide acts directly on chromatin comes from the same circle that developed it. That is why the panel lists telomerase as a reported target rather than a confirmed one: it marks where the claims point, not a mechanism settled across laboratories. On this site the peptide sits with the repair and longevity compounds.

What the research on Epithalon shows

The best-known result is a short paper by Khavinson, Bondarev and Butyugov (Bulletin of Experimental Biology and Medicine, 2003). Adding Epithalon to telomerase-negative human fetal fibroblasts produced expression of the telomerase catalytic subunit, measurable enzyme activity and longer telomeres. A follow-up in 2004 used fetal lung fibroblasts that stopped dividing at passage 34 in control cultures; treated cells made ten further divisions and were still going at passage 44.

Animal work comes from the same circle, much of it with Vladimir Anisimov at the Petrov Research Institute of Oncology in St Petersburg. The most-cited study (Biogerontology, 2003) gave female SHR mice the peptide for five days each month from three months of age until natural death. It did not change food intake, body weight or mean lifespan. It did slow the age-related loss of oestrous function, cut chromosome aberrations in bone marrow by 17.1%, extend the lifespan of the longest-lived tenth by 13.3% and lower the rate of leukaemia, while total tumour incidence was unchanged. That is a narrow result, often quoted as something broader.

Work from outside St Petersburg has begun to appear. A 2025 study in Biogerontology from Brunel University London reported dose-dependent telomere lengthening in human cell lines, through telomerase in normal cells and the alternative lengthening pathway in cancer lines. The paper needed a correction soon afterwards because the wrong figures had been printed, so cite the corrected version.

What confirmation would require

Telomerase and telomere length measured in several human cell types with standard assays, by groups with no link to the original school, and with batch identity and purity documented. Mouse lifespan studies at more than one site, in both sexes and in genetically diverse animals. Only then, pre-registered human trials with clinical end points. Human reports from the St Petersburg school concern mainly the extracts epithalamin and thymalin in older patients; we have found no randomised, placebo-controlled trial of Epithalon itself.

Epithalon doses used in published research

The mouse schedule is the most specific dosing information in the literature, and a dose per kilogram in one mouse strain does not convert into a dose for another species. No human dose has been validated, and the peptide has no approved human use. These entries summarise published study designs, not instructions for use in people.

Epithalon safety and side effects

There is not enough evidence to describe a safety profile. What exists is an absence of reported problems in small studies, which is not the same thing.

• Animal data. The authors of the 2003 mouse study concluded that long-term intermittent dosing was safe in mice. That is one strain, one sex, one laboratory.
• Human data. No controlled trial has reported systematic safety data in people, so the frequency of any adverse effect is unknown.
• Telomerase and cancer. Reactivated telomerase is a feature of most human cancers, which makes a telomerase activator a compound to watch rather than assume safe. Laboratory mice have far longer telomeres and express telomerase in more tissues, so mouse tumour data transfer poorly here.

Regulatory status of Epithalon in Europe

Epithalon has no marketing authorisation in the EU, and the panel lists its status as preclinical. Under EU medicines law, any product presented as treating or preventing disease, or used to modify physiological functions by pharmacological action, is a medicinal product and needs authorisation before sale for human use. Epithalon therefore reaches European buyers only as a research chemical. Rules on possession and personal import differ between member states, and our primer on research peptides explains where that line falls.

In sport, the WADA Prohibited List bans under S0 any pharmacological substance lacking current approval for human therapeutic use. Epithalon is not named on the list, which is not the same as being permitted; athletes should confirm its status with their anti-doping organisation.

Sourcing Epithalon for research

King Peptides does not stock Epithalon. The closest product in its range, in the sense of the same broad longevity-research area, is GHK-Cu 100 mg, and it should be taken for what it is: a different compound. GHK-Cu is a copper-binding tripeptide studied for collagen production and wound repair, so it cannot stand in for Epithalon in an experiment about telomeres. The GHK-Cu profile sets out what that literature supports.

Whichever peptide is ordered, the checks are the same. The certificate of analysis should carry the lot number printed on the vial, HPLC purity of 99% or higher and a mass spectrum matching the molecular weight: 390.3 Da for Epithalon, 340.4 Da for free GHK or about 402 Da for its copper complex. King Peptides dispatches from the Netherlands, with a shop estimate of 1–2 business days to Dutch addresses and 3–5 business days to the rest of the EU and no customs inside the union; parcels to the UK, Switzerland or Norway can be subject to import rules and duties. Packaging is neutral and tracked, and buyers confirm at checkout that they are 18 or older and ordering for research. See our certificate guide and storage guide.

Epithalon: frequently asked questions

Is Epithalon the same as epithalamin? No. Epithalamin is a pineal extract containing many peptides; Epithalon is a single synthetic tetrapeptide. Results with one cannot be transferred to the other.

Does Epithalon lengthen telomeres in people? That has not been demonstrated. Telomere lengthening has been reported in cultured human cells, recently by a group outside the original school, but no controlled human trial has measured it.

Why does it matter that one school produced most of the data? Results from a single group can carry shared methods, reagents and assumptions. Repetition by unconnected laboratories separates a real effect from a local one, and that process is only beginning here.